The Acquisition Accelerates Growth Plans for EmeritusDX within
Pharma Services
LAKE
FOREST, Calif., July 2, 2024
/PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing cancer
diagnostics and information company, today announced a definitive
agreement to acquire Sprint Diagnostics (SprintDX), with the goal
to expand its Pharma Services Division.
This acquisition is not just an addition of
services, but a pivotal step towards our strategic expansion in the
pharma services arena," Robert
Embree, CEO
This acquisition marks a significant milestone for EmeritusDX in
its ongoing effort to enhance and diversify its service offerings
within the pharmaceutical industry. Sprint Diagnostics brings a
strong market presence and a reputation for innovative laboratory
services that complement the existing capabilities of
EmeritusDX.
"Sprint Diagnostics has established a robust track record in the
healthcare sector, known for its state-of-the-art laboratory
services and customer-centric approach. This acquisition is not
just an addition of services, but a pivotal step towards our
strategic expansion in the pharma services arena," said
Robert Embree, CEO of EmeritusDX.
"We are excited to integrate Sprint Diagnostics' expertise with our
advanced technologies and broad market reach."
The acquisition will provide EmeritusDX with valuable new
capabilities, including advanced diagnostics and increased
laboratory production capacity, which are essential for supporting
the fast-paced growth of the pharmaceutical industry. It also opens
new pathways for innovation in research and development within the
company.
"I am thrilled to welcome the Sprint Diagnostics team into our
family," said Jason Allchin,
President of EmeritusDX. "Their expertise in diagnostics will
significantly enhance our capabilities and help us to better serve
our clients' needs in the rapidly evolving healthcare landscape.
Pharma services is a space that we excited to be a part of and this
acquisition helps to accelerate our timeline."
EmeritusDX is committed to ensuring a seamless integration of
Sprint Diagnostics, prioritizing continuity of service for all
existing clients and partners. The expanded resources and combined
expertise of both companies will enhance service offerings to their
customers and provide a solid foundation for new projects and
expansions.
About EmeritusDX
EmeritusDX is a cancer diagnostic and information company. Our
expertise is in delivering actionable clinical information. Within
our world-class laboratory, we perform testing that guides the
diagnosis and treatment of cancer patients. Our partners include
hospital and private pathology laboratories, biotechnology
companies, academic institutions, contract research and
pharmaceutical development organizations, and more. We understand
the dependency on our accurate and timely results and our
commitment to excellence in this regard is unwavering.
About Sprint Diagnostics
Sprint Diagnostics is a dynamic laboratory known for its
cutting-edge diagnostic services and customer-first approach,
serving healthcare providers with reliable and efficient testing
solutions.
If you would like more information about this topic, please call
800-959-2846 or email contact@emeritusdx.com
Media Contact
Charles "Chuck" Caymus, EmeritusDX, 1 800-959-2846,
contact@emeritusdx.com, www.emeritusdx.com
View original content to download
multimedia:https://www.prweb.com/releases/emeritusdx-to-acquire-sprint-diagnostics-to-expand-its-pharma-services-division-302187601.html
SOURCE EmeritusDX